JB Capital LLC Buys 9,728 Shares of Exact Sciences Corporation $EXAS

JB Capital LLC raised its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 44.4% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 31,642 shares of the medical research company’s stock after buying an additional 9,728 shares during the period. JB Capital LLC’s holdings in Exact Sciences were worth $1,731,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Exact Sciences by 120.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock valued at $135,453,000 after acquiring an additional 1,707,287 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Exact Sciences during the 2nd quarter worth $157,805,000. Champlain Investment Partners LLC raised its position in Exact Sciences by 12.6% during the 2nd quarter. Champlain Investment Partners LLC now owns 2,529,820 shares of the medical research company’s stock valued at $134,435,000 after purchasing an additional 282,825 shares in the last quarter. Holocene Advisors LP lifted its holdings in shares of Exact Sciences by 189.5% in the 2nd quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock worth $113,995,000 after buying an additional 1,404,086 shares during the period. Finally, Bamco Inc. NY lifted its holdings in shares of Exact Sciences by 26.4% in the 2nd quarter. Bamco Inc. NY now owns 1,861,341 shares of the medical research company’s stock worth $98,912,000 after buying an additional 388,627 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on EXAS shares. Evercore ISI raised their price target on Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Canaccord Genuity Group cut shares of Exact Sciences from a “buy” rating to a “hold” rating and increased their target price for the stock from $85.00 to $105.00 in a report on Tuesday, November 25th. Wolfe Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Robert W. Baird set a $105.00 price target on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Zacks Research raised shares of Exact Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Exact Sciences presently has an average rating of “Hold” and an average target price of $85.00.

Insider Buying and Selling

In other news, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the transaction, the executive vice president directly owned 23,237 shares in the company, valued at $1,742,775. The trade was a 17.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the sale, the director owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 9,858 shares of company stock worth $695,289 in the last ninety days. 1.20% of the stock is owned by corporate insiders.

Exact Sciences Stock Down 0.0%

NASDAQ EXAS opened at $101.90 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The business has a fifty day moving average price of $87.00 and a 200 day moving average price of $64.20. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $102.66. The company has a market cap of $19.31 billion, a P/E ratio of -19.15, a P/E/G ratio of 12.58 and a beta of 1.42.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.The firm had revenue of $850.74 million for the quarter, compared to analysts’ expectations of $810.42 million. During the same period in the prior year, the firm posted ($0.21) earnings per share. The firm’s quarterly revenue was up 20.0% on a year-over-year basis. Research analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.